These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1316 related items for PubMed ID: 18240258

  • 1. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
    Heiberg MS, Koldingsnes W, Mikkelsen K, Rødevand E, Kaufmann C, Mowinckel P, Kvien TK.
    Arthritis Rheum; 2008 Feb 15; 59(2):234-40. PubMed ID: 18240258
    [Abstract] [Full Text] [Related]

  • 2. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L, Pope JE, Payne M.
    J Rheumatol; 2009 Jul 15; 36(7):1421-8. PubMed ID: 19487267
    [Abstract] [Full Text] [Related]

  • 3. The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study.
    Heiberg MS, Kaufmann C, Rødevand E, Mikkelsen K, Koldingsnes W, Mowinckel P, Kvien TK.
    Ann Rheum Dis; 2007 Aug 15; 66(8):1038-42. PubMed ID: 17213251
    [Abstract] [Full Text] [Related]

  • 4. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.
    Heiberg MS, Nordvåg BY, Mikkelsen K, Rødevand E, Kaufmann C, Mowinckel P, Kvien TK.
    Arthritis Rheum; 2005 Aug 15; 52(8):2506-12. PubMed ID: 16052584
    [Abstract] [Full Text] [Related]

  • 5. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
    Seitz M, Wirthmüller U, Möller B, Villiger PM.
    Rheumatology (Oxford); 2007 Jan 15; 46(1):93-6. PubMed ID: 16720636
    [Abstract] [Full Text] [Related]

  • 6. Comparative effectiveness of anti-tumor necrosis factor drugs on health-related quality of life among patients with inflammatory arthritis.
    Chen JS, Makovey J, Lassere M, Buchbinder R, March LM.
    Arthritis Care Res (Hoboken); 2014 Mar 15; 66(3):464-72. PubMed ID: 24022870
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis.
    Lie E, van der Heijde D, Uhlig T, Heiberg MS, Koldingsnes W, Rødevand E, Kaufmann C, Mikkelsen K, Kvien TK.
    Ann Rheum Dis; 2010 Apr 15; 69(4):671-6. PubMed ID: 19740904
    [Abstract] [Full Text] [Related]

  • 8. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.
    Fernández-Nebro A, Tomero E, Ortiz-Santamaría V, Castro MC, Olivé A, de Haro M, Portales RG, González-Mari MV, Laffón A, García-Vicuña R.
    Am J Med; 2005 May 15; 118(5):552-6. PubMed ID: 15866260
    [No Abstract] [Full Text] [Related]

  • 9. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study.
    Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Lexberg AS, Rødevand E, Kalstad S, Mikkelsen K, Kvien TK.
    Ann Rheum Dis; 2014 Jan 15; 73(1):132-7. PubMed ID: 23291385
    [Abstract] [Full Text] [Related]

  • 10. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period.
    Conti F, Ceccarelli F, Marocchi E, Magrini L, Spinelli FR, Spadaro A, Scrivo R, Valesini G.
    Ann Rheum Dis; 2007 Oct 15; 66(10):1393-7. PubMed ID: 17613555
    [Abstract] [Full Text] [Related]

  • 11. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
    Cepeda EJ, Williams FM, Ishimori ML, Weisman MH, Reveille JD.
    Ann Rheum Dis; 2008 May 15; 67(5):710-2. PubMed ID: 18079191
    [Abstract] [Full Text] [Related]

  • 12. Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register.
    Kristensen LE, Karlsson JA, Englund M, Petersson IF, Saxne T, Geborek P.
    Arthritis Care Res (Hoboken); 2010 Oct 15; 62(10):1362-9. PubMed ID: 20506310
    [Abstract] [Full Text] [Related]

  • 13. Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors.
    Iannone F, Gremese E, Atzeni F, Biasi D, Botsios C, Cipriani P, Ferri C, Foschi V, Galeazzi M, Gerli R, Giardina A, Marchesoni A, Salaffi F, Ziglioli T, Lapadula G, Gruppo Italiano di Studio sulle Early Arthritides (GISEA).
    J Rheumatol; 2012 Jun 15; 39(6):1179-84. PubMed ID: 22467933
    [Abstract] [Full Text] [Related]

  • 14. Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides.
    Biggioggero M, Favalli EG.
    Drug Dev Res; 2014 Nov 15; 75 Suppl 1():S38-41. PubMed ID: 25381973
    [Abstract] [Full Text] [Related]

  • 15. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period.
    Gomez-Reino JJ, Carmona L, BIOBADASER Group.
    Arthritis Res Ther; 2006 Nov 15; 8(1):R29. PubMed ID: 16507128
    [Abstract] [Full Text] [Related]

  • 16. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis.
    Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, Levin R, Solomon DH.
    Arthritis Rheum; 2007 Jun 15; 56(6):1754-64. PubMed ID: 17530704
    [Abstract] [Full Text] [Related]

  • 17. Hospitalizations of patients treated with anti-tumor necrosis factor-α agents -- a retrospective cohort analysis.
    Zisman D, Haddad A, Hashoul S, Laor A, Bitterman H, Rosner I, Eder L, Balbir-Gurman A, Mader R, Milman U.
    J Rheumatol; 2013 Jan 15; 40(1):16-22. PubMed ID: 23070992
    [Abstract] [Full Text] [Related]

  • 18. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
    Finckh A, Ciurea A, Brulhart L, Kyburz D, Möller B, Dehler S, Revaz S, Dudler J, Gabay C, Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis.
    Arthritis Rheum; 2007 May 15; 56(5):1417-23. PubMed ID: 17469098
    [Abstract] [Full Text] [Related]

  • 19. Comparative Persistence of Methotrexate and Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    George MD, Baker JF, Ogdie A.
    J Rheumatol; 2020 Jun 01; 47(6):826-834. PubMed ID: 31474599
    [Abstract] [Full Text] [Related]

  • 20. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
    Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Rantapää-Dahlqvist S, Saxne T, Klareskog L.
    Arthritis Rheum; 2009 Nov 01; 60(11):3180-9. PubMed ID: 19877027
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 66.